These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 28271731)

  • 1. Ketamine augmentation rapidly improves depression scores in inpatients with treatment-resistant bipolar depression.
    Rybakowski JK; Permoda-Osip A; Bartkowska-Sniatkowska A
    Int J Psychiatry Clin Pract; 2017 Jun; 21(2):99-103. PubMed ID: 28271731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Factors connected with efficacy of single ketamine infusion in bipolar depression].
    Permoda-Osip A; Skibińska M; Bartkowska-Sniatkowska A; Kliwicki S; Chłopocka-Woźniak M; Rybakowski JK
    Psychiatr Pol; 2014; 48(1):35-47. PubMed ID: 24946433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single ketamine infusion in bipolar depression resistant to antidepressants: are neurotrophins involved?
    Rybakowski JK; Permoda-Osip A; Skibinska M; Adamski R; Bartkowska-Sniatkowska A
    Hum Psychopharmacol; 2013 Jan; 28(1):87-90. PubMed ID: 23124710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar Depression.
    Xu AJ; Niciu MJ; Lundin NB; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Machado-Vieira R; Zarate CA
    Neural Plast; 2015; 2015():858251. PubMed ID: 26137324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion.
    Pennybaker SJ; Niciu MJ; Luckenbaugh DA; Zarate CA
    J Affect Disord; 2017 Jan; 208():560-566. PubMed ID: 27839782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline vitamin B12 and folate levels do not predict improvement in depression after a single infusion of ketamine.
    Lundin NB; Niciu MJ; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Brutsche NE; Machado-Vieira R; Zarate CA
    Pharmacopsychiatry; 2014 Jul; 47(4-5):141-4. PubMed ID: 24955551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression.
    Park M; Newman LE; Gold PW; Luckenbaugh DA; Yuan P; Machado-Vieira R; Zarate CA
    J Psychiatr Res; 2017 Jan; 84():113-118. PubMed ID: 27718369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Both Serum Brain-Derived Neurotrophic Factor and Interleukin-6 Levels Are Not Associated with Therapeutic Response to Lamotrigine Augmentation Therapy in Treatment-Resistant Depressive Disorder.
    Kagawa S; Mihara K; Suzuki T; Nagai G; Nakamura A; Nemoto K; Kondo T
    Neuropsychobiology; 2017; 75(3):145-150. PubMed ID: 29332095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.
    Murrough JW; Burdick KE; Levitch CF; Perez AM; Brallier JW; Chang LC; Foulkes A; Charney DS; Mathew SJ; Iosifescu DV
    Neuropsychopharmacology; 2015 Mar; 40(5):1084-90. PubMed ID: 25374095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.
    Ionescu DF; Luckenbaugh DA; Niciu MJ; Richards EM; Slonena EE; Vande Voort JL; Brutsche NE; Zarate CA
    J Clin Psychiatry; 2014 Sep; 75(9):e932-8. PubMed ID: 25295436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parsing the heterogeneity of depression: An exploratory factor analysis across commonly used depression rating scales.
    Ballard ED; Yarrington JS; Farmer CA; Lener MS; Kadriu B; Lally N; Williams D; Machado-Vieira R; Niciu MJ; Park L; Zarate CA
    J Affect Disord; 2018 Apr; 231():51-57. PubMed ID: 29448238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical predictors of ketamine response in treatment-resistant major depression.
    Niciu MJ; Luckenbaugh DA; Ionescu DF; Guevara S; Machado-Vieira R; Richards EM; Brutsche NE; Nolan NM; Zarate CA
    J Clin Psychiatry; 2014 May; 75(5):e417-23. PubMed ID: 24922494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder.
    Rong C; Park C; Rosenblat JD; Subramaniapillai M; Zuckerman H; Fus D; Lee YL; Pan Z; Brietzke E; Mansur RB; Cha DS; Lui LMW; McIntyre RS
    Int J Environ Res Public Health; 2018 Apr; 15(4):. PubMed ID: 29673146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KETAMINE FOR TREATMENT-RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE.
    Bobo WV; Vande Voort JL; Croarkin PE; Leung JG; Tye SJ; Frye MA
    Depress Anxiety; 2016 Aug; 33(8):698-710. PubMed ID: 27062450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression.
    Luckenbaugh DA; Ibrahim L; Brutsche N; Franco-Chaves J; Mathews D; Marquardt CA; Cassarly C; Zarate CA
    Bipolar Disord; 2012 Dec; 14(8):880-7. PubMed ID: 22978511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of adipokines in the rapid antidepressant effects of ketamine.
    Machado-Vieira R; Gold PW; Luckenbaugh DA; Ballard ED; Richards EM; Henter ID; De Sousa RT; Niciu MJ; Yuan P; Zarate CA
    Mol Psychiatry; 2017 Jan; 22(1):127-133. PubMed ID: 27046644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benzodiazepines may reduce the effectiveness of ketamine in the treatment of depression.
    Ford N; Ludbrook G; Galletly C
    Aust N Z J Psychiatry; 2015 Dec; 49(12):1227. PubMed ID: 26058787
    [No Abstract]   [Full Text] [Related]  

  • 18. Continuation phase intravenous ketamine in adults with treatment-resistant depression.
    Vande Voort JL; Morgan RJ; Kung S; Rasmussen KG; Rico J; Palmer BA; Schak KM; Tye SJ; Ritter MJ; Frye MA; Bobo WV
    J Affect Disord; 2016 Dec; 206():300-304. PubMed ID: 27656788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo-control study.
    Chen MH; Cheng CM; Gueorguieva R; Lin WC; Li CT; Hong CJ; Tu PC; Bai YM; Tsai SJ; Krystal JH; Su TP
    Neuropsychopharmacology; 2019 Nov; 44(12):2112-2118. PubMed ID: 31421635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistent antidepressant effect of low-dose ketamine and activation in the supplementary motor area and anterior cingulate cortex in treatment-resistant depression: A randomized control study.
    Chen MH; Li CT; Lin WC; Hong CJ; Tu PC; Bai YM; Cheng CM; Su TP
    J Affect Disord; 2018 Jan; 225():709-714. PubMed ID: 28922734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.